馬里蘭州蓋瑟斯堡2024年2月13日 /美通社/ -- YS Biopharma Co., Ltd.(納斯達克股票代碼:YS) (「YS Biopharma」)及其子公司(「YS Group」(簡稱「公司」), 一家致力於發現、開發、製造和銷售新一代傳染病和癌症疫苗和治療性生物制劑的全球生物製藥公司, 今天宣佈已與一家機構投資者(簡稱「買方」)簽訂了一項股票購買協議(簡稱「購買協議」), 定向增發95,269,762股普通股。截止到今天, 包括本次私募融資, 公司已發行188,327,959股普通股。 

公司董事、總裁兼首席執行官邵博士評論道:「我們很自豪地宣佈, 我們通過發行普通股的方式進行4000萬美元的私募。這次股權融資不涉及發行任何認股權證或期權, 我們賦予投資者直接的股權所有權, 使他們的利益與現有股東的利益保持一致, 為依生生物的長期成功而努力。這筆資金的注入大大改善和加強了我們的資產負債表。它增強了我們的現金狀況, 增強了流動性, 並提供了額外的資金。」

該輪融資所購買的股份不受1933年證券法(根據該法案頒布的第S條修訂的「證券法」)的註冊要求的約束。此次私募是在開曼群島大法院於2023年12月22日解除強制令後進行的。本購買協議包含本公司和認購方的常規聲明、保證和承諾, 以及此類交易的常規賠償條款。公司還授予認購方常規註冊權。

關於依生生物

依生生物是一家國際性生物製藥公司, 致力於發現、開發、生產和商業化新一代的疫苗和治療性生物制劑, 治療領域專注於傳染病和癌症。公司管理團隊在疫苗和製藥行業具有全球視野和豐富的經營地的專業知識優勢。公司開發了自主研發的PIKA®免疫調節技術平台和一系列針對狂犬病、乙肝、帶狀皰疹、流感、冠狀病毒的預防和治療性生物制劑。依生生物在中國、新加坡、美國、阿拉伯聯合酋長國和菲律賓擁有超過800名員工。

投資者關係聯繫人
Robin Yang
Partner, ICR, LLC
電話: +1 (212) 537-4035
郵箱: YSBiopharma.IR@icrinc.com

Cautionary Statement Regarding Forward-Looking Statements

This press release contains ''forward-looking statements'' within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the expected growth of YS Biopharma, the development progress of all product candidates, the progress and results of all clinical trials, YS Biopharma's ability to source and retain talent, and the cash position of YS Biopharma following the closing of the Business Combination. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of YS Biopharma's management and are not predictions of actual performance.

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Although YS Biopharma believes that it has a reasonable basis for each forward-looking statement contained in this press release, YS Biopharma cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, there are risks and uncertainties described in the final prospectus relating to the proposed Business Combination, and other documents filed by YS Biopharma from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

YS Biopharma cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, the ability to recognize the anticipated benefits of the Business Combination, costs related to the transaction, the impact of the global COVID-19 pandemic, the risk that the transaction disrupts current plans and operations as a result of the consummation of the transaction, the outcome of any potential litigation, government or regulatory proceedings, the sales performance of the marketed vaccine product and the clinical trial development results of the product candidates of YS Biopharma, and other risks and uncertainties, including those included under the heading "Risk Factors" in the final prospectus filed with the SEC on February 8, 2023, as supplemented on February 21, 2023, and other filings with the SEC. There may be additional risks that YS Biopharma does not presently know or that YS Biopharma currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of YS Biopharma as of the date of this press release. Subsequent events and developments may cause those views to change. However, while YS Biopharma may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of YS Biopharma as of any date subsequent to the date of this press release. Except as may be required by law, YS Biopharma does not undertake any duty to update these forward-looking statements.